Isopto Max

Quick links to important sections

Isopto Max

Selected form

Method of action: Pain Reliever

Treatment option: Pain/ Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isopto Max

Quick Facts

Property Description
Active Ingredients Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate
Form Sterile Ophthalmic Suspension (Drops), Ophthalmic Ointment
Pharmacological Class Ophthalmic Steroids with Anti-infectives
Common Use Management of inflammatory ocular conditions where bacterial infection risk exists
Origin Synthetic Corticosteroid and Semi-synthetic Antibiotics

Classification and Composition

Isopto Max is a prescription-only ophthalmic combination drug administered by the topical ophthalmic route, specifically classified as an Ophthalmic Steroid with Anti-infectives. This medication is a triple-ingredient formulation utilizing the synthetic corticosteroid Dexamethasone and two antibiotics, Neomycin Sulfate and Polymyxin B Sulfate. It is available in two distinct preparations for application to the eye: a Sterile Ophthalmic Suspension (liquid drops) and a Sterile Ophthalmic Ointment. The product's structure, which combines one steroid and two antibiotics, is clinically recognized for providing broad-spectrum coverage against many common ocular pathogens.

Primary Rationale for this Combined Therapy

The primary rationale for this formulation is to offer simultaneous, high-potency anti-inflammatory action and necessary antibacterial protection in a single product. The Dexamethasone component is included to suppress the acute inflammatory response, thereby reducing symptoms like swelling and redness. The anti-infective component, which combines the effects of Neomycin and Polymyxin B, is supported by pharmacological studies for its activity against a wide range of susceptible bacteria, including both Gram-positive and Gram-negative organisms. This combined approach is reserved for situations where a clinician determines a corticosteroid is essential to reduce inflammation and an anti-infective component is necessary to address an existing or potential bacterial contamination, simplifying the treatment regimen for a specific patient group.

Regulatory References

  1. DailyMed Label for Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Suspension

What side effects are possible with Isopto Max?

Possible Side Effects and Safety Information

The safety profile for Isopto Max (Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate) is primarily structured around local ocular reactions and risks associated with its components, as documented in official regulatory labeling.

Most reported adverse reactions fall under Eye Disorders and are classified as Common, including transient local ocular discomfort such as stinging or burning upon application, and ocular hyperaemia (redness). Uncommon reactions include local allergic sensitization or hypersensitivity, particularly linked to the Neomycin antibiotic component.

Documented Serious Safety Risks

Official labeling emphasizes several serious, duration-dependent risks related to the corticosteroid component. Prolonged use is specifically associated with an elevated risk of Increased Intraocular Pressure (IOP), which can potentially lead to optic nerve damage and visual field defects. Long-term use also increases the risk of forming a Posterior Subcapsular Cataract.

Due to its composition, the medicine is contraindicated in most viral and fungal diseases of the eye (e.g., epithelial Herpes Simplex keratitis), as the steroid component may worsen the infection. A risk of Perforation of the Globe is also documented in cases where the cornea or sclera is already thin.

Regulatory Context and Limitations

The safety profile notes that the medicine is contraindicated in individuals with known hypersensitivity to any of its components. Safety and effectiveness in pediatric patients have not been established. When used for ten days or longer, the label specifies that intraocular pressure should be checked frequently.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented overdose information based strictly on government regulatory sources.


Documented Overdose Scenarios

Scenario Official Regulatory Statements
Acute Ocular Overdose No toxic effects are expected following an acute overdose via the topical route of administration.
Accidental Ingestion The primary overdose scenario addressed is unintentional peroral intake (accidental swallowing) of the ophthalmic product.
Expected Toxicity Dangerous or toxic systemic effects are not anticipated from accidental ingestion of the low-volume ophthalmic formulation.

Required Emergency Actions

Action Required Official Regulatory Statements
Immediate Help Immediate medical attention must be sought if the ophthalmic suspension or ointment is accidentally swallowed (ingested).
Emergency Contact Official guidance recommends contacting a Poison Control Center or emergency services immediately following accidental ingestion.

Overdose Management

No specific antidote for this combination product is documented in the official prescribing information. Management is defined as symptomatic and supportive treatment. Hospital monitoring may be required following significant accidental ingestion to observe for any potential systemic effects. Regulatory documents do not specify increased overdose risk for particular populations (e.g., pediatric or elderly).

Therapeutic Uses of Isopto Max

What Isopto Max Treats: Main Uses and Benefits

This combination medication is generally used across conditions presenting with localized discomfort, characterized by the presence of symptoms related to inflammatory or irritative states alongside bacterial concerns. Applied across domains where additional symptomatic support is needed, this therapy is considered relevant in conditions involving episodic or fluctuating manifestations, such as infectious conjunctivitis and chronic inflammatory states like anterior uveitis.

The therapy is used to help address symptom clusters that may become intense or disruptive and create noticeable interference with daily stability. This includes managing pronounced manifestations such as eye swelling, persistent redness, and intense itching. Providing this supportive relief contributes to easing the overall symptom load and supports patients during difficult episodes by easing distress.

The medication is also applied in specialized clinical settings marked by conditions where functional stability becomes affected, such as care following ocular insults from chemicals or foreign objects. It may assist with maintaining functional stability and is commonly used when short-term symptomatic assistance is needed.


Quick Fact: Managing Ocular Symptoms
Symptom Domain Inflammation and Irritation
Common Scenarios Infectious episodes with swelling, post-injury care, or chronic inflammatory conditions.
Benefit Focus Supports the management of swelling and redness, which contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

This section summarizes official regulatory information defining who is eligible to use Isopto Max (Dexamethasone/Neomycin/Polymyxin B Ophthalmic Suspension/Ointment) and who is formally excluded.

Contraindicated Populations and Conditions: Use of this medicine is prohibited for patients with a known hypersensitivity or allergic reaction to Dexamethasone, Neomycin, Polymyxin B, or any other component in the formulation.

It is also formally contraindicated in the presence of specific eye infections, including:

  • Herpes Simplex Keratitis (Dendritic Keratitis)
  • Vaccinia, Varicella (Chickenpox), or other viral diseases of the cornea and conjunctiva
  • Fungal or Mycobacterial infections of the eye
  • Untreated purulent infection of the eye

Populations Requiring Special Consideration:

  • Children under 2 years of age: Use is generally not established or not recommended due to limited data.
  • Pregnancy and Breastfeeding: Use is not recommended due to insufficient data regarding fetal and infant safety. The decision to use this medicine must be based on a clear clinical need, weighing the potential benefit against the unknown risks. Contact lens wearers must remove lenses prior to application.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Isopto Max (Dexamethasone/Neomycin/Polymyxin B ophthalmic) is structured around management of potential systemic exposure and required administration timing rules for concurrent eye treatments. Due to the product's topical ophthalmic route, the range of systemic drug interactions documented in regulatory labeling is limited.

Documented Interaction Patterns

Interacting Substance Category Official Regulatory Description
Systemic CYP3A4 Inhibitors Co-administration with strong systemic inhibitors, such as Ritonavir or Cobicistat, may increase systemic exposure to the Dexamethasone component. This pharmacokinetic interaction carries a risk of systemic corticosteroid effects, and is especially noted as a concern in the pediatric population.
Other Topical Ophthalmic Products Simultaneous administration of multiple topical eye preparations requires a specific timing separation. Products must be administered at least five (5) minutes apart to prevent washout and ensure adequate contact time on the eye surface.
Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) The combined use of topical steroids and topical NSAIDs may increase the potential for complications related to corneal healing.

This information defines a set of constraints focusing on metabolic inhibition, administration sequencing, and local pharmacodynamic effects, as described by official government regulatory documents.

Mechanism of Action

Isopto Max is a fixed-combination ophthalmic preparation containing dexamethasone and tobramycin. Its mechanism of action involves dual, distinct pathways:

  1. Dexamethasone Mechanism: This component acts as a glucocorticoid receptor agonist. Dexamethasone crosses the cell membrane, binding to the cytosolic glucocorticoid receptor (GR). The activated receptor-ligand complex then translocates to the nucleus, where it modulates gene expression. This genomic effect inhibits the transcription of pro-inflammatory mediators, including cyclooxygenase-2 (COX-2) and various cytokines and chemokines, thereby interfering with the upstream signaling cascades that characterize the inflammatory response.

  2. Tobramycin Mechanism: Tobramycin primarily functions by binding irreversibly to the 30S subunit of the bacterial ribosome. This binding interferes with the initiation complex formation and causes misreading of the mRNA template, resulting in the production of non-functional, truncated proteins. The incorporation of these aberrant proteins into the bacterial cell membrane leads to increased permeability and cell death.

The combined action provides receptor-mediated transcriptional modulation and ribosomal inhibition within the target tissues.

Dosage and Administration Information

How Isopto Max is Used: Official Administration Guidelines

Isopto Max (a combination of Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate) is strictly administered via the topical ophthalmic route (on the eye) only. Standard usage guidelines for the sterile ophthalmic suspension and ointment are established for proper administration.

Official Dosing and Schedule

Usage Element Guideline
Dose (Suspension) One or two drops applied to the affected eye(s).
Dose (Ointment) A small amount (e.g., a 1/2 inch ribbon) into the conjunctival sac.
Frequency Mild/Moderate Disease: Typically up to four to six times daily. Severe Disease: May be used as often as hourly, then tapered as symptoms subside.
Treatment Duration The initial prescription should not be refilled without a physician re-evaluation. If a satisfactory response is not obtained within 3–4 days, the diagnosis must be re-evaluated.

Key Administration Procedures

Several practical steps are emphasized for proper use:

  • Preparation: The ophthalmic suspension must be shaken well before each use.
  • Contamination: The tip of the dropper or tube must not touch the eye, eyelid, or any surface to maintain sterility.
  • Co-Administration: If using other topical eye products, they must be administered at least 5 minutes apart from Isopto Max.
  • Special Populations: No dosage adjustment is needed for older adults or those with hepatic/renal impairment due to the low systemic absorption.
  • Contact Lenses: Soft contact lenses must be removed before instillation and may be reinserted only after a waiting period (e.g., 15 minutes).

Recent Clinical Evidence

Research evidence / Overview of studies for Isopto Max

Evidence for Use in Acute and Chronic Blepharitis and Conjunctivitis

Research exploring the fixed combination of Dexamethasone, Neomycin, and Polymyxin B was evaluated in studies focused on external inflammatory eye conditions, such as bacterial blepharitis and conjunctivitis. This combination was studied for conditions characterized by fluctuating manifestations where both inflammation and bacterial involvement were factors. The primary clinical evaluation was studied in short-term, randomized, double-masked comparative clinical trials where researchers measured objective and patient-reported outcomes.

The findings describe patterns observed in the studies related to measurement of change in bacterial load and the assessment of bacterial eradication rates. Comparative trials described measurements that were compared between the triple-combination product and the corticosteroid component used alone. This evidence contributes to the broader evidence landscape describing symptom patterns over defined time intervals.


Evidence for Use in Severe Ocular Inflammation and Post-Injury Care

For the management of more severe inflammatory conditions, such as chronic anterior uveitis or care following corneal injury, the evidence structure is different. Research examined the combination’s use in these settings by relying on the established, independent efficacy profiles of its component drugs. Specifically, the presence of the combination's anti-infective components was observed in research settings alongside the anti-inflammatory properties of Dexamethasone.

Studies explored the use in patients with inflammation localized to the anterior segment of the globe. The outcomes related to systemic or functional imbalance that were monitored included measurements of inflammatory signs and surveillance for the prevention of secondary bacterial infection. Findings indicate patterns related to the concurrent evaluation of anti-inflammatory and anti-infective action in these conditions marked by functional limitations.


Gaps and Uncertainties in the Research Record

The research base provides an insight into short-term changes for specific conditions. Key limitations include the fact that follow-up durations were limited in the primary comparative trials. Long-term outcomes are not well characterized by the existing trial data. Comparative evidence is lacking for many specific subgroups, and for less common indications like uveitis, the evidence is often extrapolated from studies of the individual component actions.

Key Studies & References Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate Ophthalmic Suspension (DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Isopto Max (FAQ)


Q: How quickly should I expect to see an improvement after starting Isopto Max?

Official regulatory guidelines focus on the necessary duration for clinical checks. They state that if a satisfactory response is not obtained within 3–4 days of starting the medication, the diagnosis should be re-evaluated, as described in official guidelines.


Q: Is Isopto Max known to cause increased pressure inside the eye (glaucoma)?

Regulatory documents state that prolonged use of the corticosteroid component (Dexamethasone) is associated with an elevated risk of Increased Intraocular Pressure (IOP). This elevated pressure may potentially lead to optic nerve damage, a condition related to glaucoma. The labeling specifies that intraocular pressure should be checked frequently when the medication is used for 10 days or longer.


Q: What is the recommended period of time for using Isopto Max?

Official labeling focuses on the limits of use before re-evaluation, stating that the initial prescription should not be refilled without a physician re-evaluation. The regulatory documents state that when treatment extends for 10 days or longer, the intraocular pressure should be checked frequently.


Q: Is there a risk of antibiotic resistance with Isopto Max?

According to regulatory documents, the prolonged use of antibiotic components like Neomycin and Polymyxin B may lead to the overgrowth of non-susceptible organisms. This risk is associated with the potential for the overgrowth of non-susceptible organisms, which is often referred to in regulatory contexts as a superinfection.


Q: Can the corticosteroid in Isopto Max mask symptoms of another infection?

Yes, official regulatory warnings indicate that in certain acute infections of the eye, such as those that are purulent (containing pus) or parasitic, the steroid component may mask the symptoms of infection or enhance an existing one. This statement appears in the Warnings section of the product labeling to inform patients about the potential risks.


Q: What should I do if my eye symptoms get worse while using the drops?

Official documents advise that if eye symptoms such as pain, redness, swelling, or irritation get worse or persist during treatment, a doctor or pharmacist should be consulted, as advised in the official documents.


Q: What is the difference between Isopto Max eye drops and the eye ointment formulation?

Both the eye drops (suspension) and the eye ointment contain the same three active ingredients: Dexamethasone, Neomycin, and Polymyxin B. The difference is primarily in the formulation's inactive ingredients (vehicle or base) used to create the liquid suspension versus the semi-solid ointment base.


Q: Does Isopto Max treat all types of eye infections?

No. Official information indicates the medication is active against a wide range of susceptible bacterial pathogens. However, it is contraindicated (prohibited from use) for most viral, fungal, and mycobacterial infections of the eye. It is also not fully effective against certain bacterial strains.


Q: Can Isopto Max be used for viral pink eye (conjunctivitis)?

No. The medication is formally contraindicated (prohibited) for patients with most viral diseases of the eye, including Herpes Simplex Keratitis, Vaccinia, and Varicella. The medication is contraindicated due to the potential for the steroid component to enhance or worsen certain viral infections.


Q: Can Isopto Max cause a temporary change in vision or blurry sight?

Yes. Regulatory information lists temporary blurred vision as an expected effect that may occur when the medication is applied. This usually resolves quickly after application.


Q: What are the signs that I might be having an allergic reaction to Isopto Max?

Allergic reactions are possible, particularly due to the Neomycin component. Signs documented in official sources can include itching, redness, and swelling of the eyes, or more serious systemic reactions such as hives, swelling of the face/throat, difficulty breathing, or a blistering skin rash.


Q: Will using Isopto Max make my eye more sensitive to light (photophobia)?

Yes. Increased sensitivity to light, known as photophobia, is documented in official sources as a possible side effect of the medication.


Q: Is Isopto Max considered a broad-spectrum antibiotic eye treatment?

The combined antibiotic components (Neomycin and Polymyxin B) are described in regulatory documents as active against a wide range of susceptible bacteria, including many Gram-positive and Gram-negative organisms, which means it targets a wide range of bacteria.


Q: Does Isopto Max contain any preservatives that might irritate the eye?

Yes, the eye drop suspension contains Benzalkonium chloride as a preservative, which is noted in regulatory documents as potentially causing eye irritation, especially in individuals with pre-existing dry eye or corneal conditions. The ointment may contain other preservatives like methylparaben and propylparaben.


Q: Can Isopto Max be used to treat ear infections or other body parts?

No. The product is strictly formulated and indicated for use via the topical ophthalmic route (on the eye) only, as specified in regulatory documents. The medication is not indicated for use in the ear or any other part of the body.


Q: How can I tell the difference between a serious side effect and a common one?

Official patient information distinguishes between common reactions, such as temporary stinging or burning upon application, and serious, less common risks associated with long-term use. Serious risks include complications like increased eye pressure (IOP) or cataract formation, which require a doctor's attention.


Q: Does Isopto Max interact with over-the-counter eye drops like artificial tears?

Regulatory administration procedures state that if any other topical eye products, including over-the-counter drops, are used concurrently, they must be administered at least five (5) minutes apart from Isopto Max. This timing separation is required for all concurrent topical eye products to ensure adequate contact time and efficacy.


Q: Why is the steroid component often used after eye surgery?

The corticosteroid component is included because it is indicated for managing inflammatory conditions of the eye's anterior segment. This includes inflammation following various forms of corneal injury (such as from burns or foreign bodies), which is often the therapeutic objective in a post-surgical setting.


Q: Can I drive a car immediately after applying Isopto Max?

Official warnings advise caution when performing activities that require clear vision. Since the medication can cause temporary blurred vision immediately after application, official warnings state that driving or operating machinery may need to be avoided until vision is clear and the activity can be performed safely.


Q: Is Isopto Max used only for the external part of the eye?

The medication is indicated for conditions affecting the anterior segment of the globe. This covers the front part of the eye, including the eyelid lining (palpebral conjunctiva), the white of the eye (bulbar conjunctiva), and the cornea.


Q: What is the difference between Isopto Max and Isopto Atropine?

Isopto Max is a fixed combination of a steroid (Dexamethasone) and two antibiotics. Isopto Atropine (Atropine Sulfate) is a completely different medication that is classified as an anticholinergic agent used for a different purpose: to dilate the pupil and temporarily paralyze the eye's focusing mechanism.

How should Isopto Max be stored and disposed of?

How to Store and Dispose of Isopto Max?

This information is based on official government regulatory documents regarding the storage and disposal of ophthalmic products containing Neomycin, Polymyxin B, and Dexamethasone.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (typically 59 F to 77 F / 15 C to 25 C). The ointment form may also be refrigerated.
Protection Keep away from excessive heat, moisture, and direct light.
Handling Keep the container tightly closed. Do not allow the dispenser tip to touch any surface, including the eye.
Safety Keep out of the reach of children.

Disposal Instructions

Official instructions require that the product be properly discarded when it is expired or no longer needed. Do not flush the medication down the toilet or pour it into a drain unless specifically instructed by a healthcare professional or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isopto Max found in:

A-Z Index: